When was Rgenta founded?

Rgenta was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Rgenta located?

Rgenta is headquartered in Cambridge, United States. It is registered at Cambridge (United States).

How many employees does Rgenta have?

As of Aug 31, 2026, the latest employee count at Rgenta is 33.

Is Rgenta a funded company?

Rgenta is a funded company, having raised a total of $90M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 05, 2020.

When was the latest funding round of Rgenta?

Rgenta's latest funding was a $***** Series A round on 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.63B in funding in 2026 to date.

Where does Rgenta rank among its competitors?

Rgenta ranks 450th amongst 4390 active competitors, of which 1461 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Rgenta?

Rgenta's top competitors include Jazz Pharmaceuticals, BeiGene and Alnylam. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Rgenta - 2026 Company Profile, Team, Funding & Competitors

Rgenta is a series A company based in Cambridge (United States), founded in 2018 by Zhiping Weng. It operates as a Developer of RNA-based therapeutics for multiple disorders. Rgenta has raised $90M in funding from investors like Boehringer Ingelheim Venture Fund, AstraZeneca and Matrix Partners China. The company has 4390 active competitors, including 1461 funded and 994 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.

Company Details

Developer of RNA-based therapeutics for multiple disorders. It is building compound libraries likely to recognize the RNA target sites and modulate their function, particularly those mediated by the regulatory proteins. The data-driven mRNA target identification platform accounts for cell type-specific target regulation and predicts the biological consequences of target modulation.

Website: rgentatx.com
Email ID: *****@rgentatx.com
Registered Address: Cambridge (United States)

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Series A

Total Funding

$90M in 5 rounds

Latest Funding Round

Series A, 2025, $*****

Investors

Boehringer Ingelheim Venture Fund & 12 more

Ranked

450^th among 4390 active competitors

Employee Count

33 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 4262 more

View Rgenta's full profile

Rgenta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Rgenta Therapeutics, Inc., CIN: 82-5268874 , United States, Active	Dec 31, 2017	-	11 (As on Dec 31, 2021)	-

Rgenta has raised a total funding of $90M over 5 rounds. Its first funding round was on Feb 05, 2020. Its latest funding round was a Series A round on 2025 for $*****. 1 investor participated in its latest round. Rgenta has 13 institutional investors.

Here is the list of recent funding rounds of Rgenta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2025	3359	Series A	3123	8172	8579	2517
Nov 29, 2022	3306336	Series A	3354324	6322429	3465670	Delos Capital & 7 more
May 25, 2021	7908489	Seed	6614116	1286871	3187562	1977283

Access funding benchmarks and valuations. Sign up today!

View details of Rgenta's funding rounds and investors

The founders of Rgenta is Zhiping Weng.

Here are the details of Rgenta's key team members:

Zhiping Weng: Co-Founder of Rgenta.
Contact Info: 3 email addresses

View details of Rgenta's Founder profiles and Board Members

Rgenta's employee count trend

Rgenta has 33 employees as of Aug 26. Here is Rgenta's employee count trend over the years:

Uncover Rgenta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rgenta include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Rgenta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
4th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
7th	LifeCell 2004, Chennai (India), Series B	A stem cell banking company specializing in cord blood and tissue preservation	$61.2M	Orbimed, Helion Venture Partners & 74 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
10th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
450th	Rgenta 2018, Cambridge (United States), Series A	Developer of RNA-based therapeutics for multiple disorders	$90M	EQT, Vivo Capital & 11 others	56/100